Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
Open Access
- 1 August 2022
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (11) , 1576-1584
Abstract
Objectives Premature cardiovascular events in systemic lupus erythematosus (SLE) contribute to morbidity and mortality, with no effective preventive strategies described to date. Immune dysregulation and metabolic disturbances appear to play prominent roles in the induction of vascular disease in SLE. The peroxisome proliferator activated receptor-gamma agonist pioglitazone (PGZ suppresses vascular damage and immune dysregulation in murine lupus and improves endothelial dysfunction in other inflammatory diseases. We hypothesised that PGZ could improve vascular dysfunction and cardiometabolic parameters in SLE. Methods Eighty SLE subjects with mild to severe disease activity were randomised to a sequence of PGZ followed by placebo for 3 months, or vice versa, in a double-blind, cross-over design with a 2-month wash-out period. Primary endpoints were parameters of endothelial function and arterial inflammation, measured by multimodal assessments. Additional outcome measures of disease activity, neutrophil dysregulation, metabolic disturbances and gene expression studies were performed. Results Seventy-two subjects completed the study. PGZ was associated with a significant reduction in Cardio-Ankle Vascular Index (a measure of arterial stiffness) compared with placebo. Various metabolic parameters improved with PGZ, including insulin resistance and lipoprotein profiles. Circulating neutrophil extracellular trap levels also significantly decreased with PGZ compared with placebo. Most adverse events experienced while on PGZ were mild and resolved with reduction in PGZ dose. Conclusion PGZ was well tolerated and induced significant improvement in vascular stiffness and cardiometabolic parameters in SLE. The results suggest that PGZ should be further explored as a modulator of cardiovascular disease risk in SLE. Trial registration number NCT02338999.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (ZIAAR041199)
This publication has 39 references indexed in Scilit:
- The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid ArthritisJournal of the American Heart Association, 2013
- Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studiesDiabetic Medicine, 2013
- Lupus Atherosclerosis Prevention Study (LAPS)Annals of the Rheumatic Diseases, 2011
- An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENAAnnals of the Rheumatic Diseases, 2011
- The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine LupusThe Journal of Immunology, 2009
- Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosusAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetesCardiovascular Diabetology, 2009
- ‘Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosusRheumatology, 2005
- Beneficial effects of PPAR-? ligands in ischemia?reperfusion injury, inflammation and shockCardiovascular Research, 2005
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997